The clinical effects of single-agent Xeloda (Capecitabine) and related risk factors in treatment of patients with advanced colorectal cancer
- VernacularTitle:单药希罗达治疗晚期结直肠癌的临床疗效及相关因素分析
- Author:
Lijiang HAN
;
Xinjiang SONG
- Publication Type:Journal Article
- Keywords:
Xeloda (Capecitabine);
advanced colorectal cancer;
clinical effects
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(1):111-112,115
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effects of single-agent Xeloda (Capecitabine) therapy and the related risk factors in patients with advanced colorectal cancer. Method Seventy-eight patients with advanced colorectal cancer were treated with oral Xeloda, 1250 mg/m 2 twice daily, on days 1-14 every 21 days. At least 2 cycles were administered. The short-term clinical effects were evaluated, and the related risk factors were tested by Logistic regression analysis. Results The overall response rate was 32.05%with 5 cases complete response (CR), 20 cases partial response (PR), 31 cases stable disease (SD), 22 cases progress disease (PD). The Logistic regression analysis showed that the age (OR=1.52, 95%CI 1.015~2.319), fast blood glucose (OR=1.30, 95%CI 1.483~3.677), albumin (OR=1.98, 95%CI 1.526~2.572), ALT (OR=2.37, 95%CI 1.621~3.509) and AST (OR=2.21, 95%CI 1.526~2.572) were independent risk factors for inefficient treatment. Conclusion The single-agent Xeloda (Capecitabine) is an efficacious treatment for the patients with advanced colorectal cancer. However, the inefficient rate is also high and it relates to a variety of factors. We should comprehensively evaluate the patients to improve the short-term clinical effects.
